Wugen: Funding, Investors & Team (Sep 2026)
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
Wugen has raised $322M across 3 funding rounds on record, the most recent a Series C of $35.0M announced in Jul 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Wugen Company Profile and Key Stats
Latest funding round on record: Jul 2026.
Wugen Funding Rounds
Wugen raised $172M in a Series B announced in Jul 2021.
4.1 years later, a Series C of $115M was announced in Aug 2025.
11 months later, a Series C of $35.0M was announced in Jul 2026.
Wugen Investors
16 investors are recorded in total; the 5 named above are those the record identifies.
Wugen Founders and Leadership Team
Contact details for the Wugen team: 2 of 4 have an email address on file.
Start 14-day free trial →Wugen Funding Compared to Other Biotechnology Startups
Wugen's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Wugen in Biotechnology and St Louis
Companies Similar to Wugen
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Wugen Funding FAQs
What does Wugen do?
Wugen is a developer of a novel CAR-T therapy platform intended for T-Cell Malignancies.The company's state-of-the-art gene editing technologies and cutting-edge Car-T cell therapy address some of the challenges that have limited the clinical development of allogeneic Car-T cells, enabling patients aid in the treatment of cancer.
How much funding has Wugen raised?
Wugen has raised $322M across 3 rounds on record. The most recent is a Series C of $35.0M announced in Jul 2026.
When did Wugen last raise funding?
Wugen's most recent funding round on record is a Series C of $35.0M, announced in Jul 2026.
Who has invested in Wugen?
Investors on record for Wugen include Sands Capital Ventures, Alpha Wave Global, Intermediate Capital Group, Fidelity, Abingworth. FundedIQ records 16 investors in total.
Who founded Wugen?
FundedIQ lists Matthew Cooper (Founder) at Wugen.
Who is the CEO of Wugen?
Kumar is listed as Chief Executive Officer at Wugen.
Where is Wugen headquartered?
Wugen is based in St Louis, Missouri, United States.
How many employees does Wugen have?
Wugen is in the 11-50 employee band.
When was Wugen founded?
Wugen was founded in 2018.
How does Wugen's funding compare to other Biotechnology startups?
Wugen's latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Wugen Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Wugen is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.